Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020)

Historic Preferred Stock Liabilities for Outlook Therapeutics (OTLK) over the last 4 years, with Q1 2020 value amounting to $6.5 million.

  • Outlook Therapeutics' Preferred Stock Liabilities rose 2834.33% to $6.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was $6.5 million, marking a year-over-year increase of 2834.33%. This contributed to the annual value of $5.4 million for FY2019, which is 1320.1% up from last year.
  • Latest data reveals that Outlook Therapeutics reported Preferred Stock Liabilities of $6.5 million as of Q1 2020, which was up 2834.33% from $8.2 million recorded in Q4 2019.
  • Outlook Therapeutics' Preferred Stock Liabilities' 5-year high stood at $18.3 million during Q1 2018, with a 5-year trough of $2.9 million in Q3 2017.
  • In the last 4 years, Outlook Therapeutics' Preferred Stock Liabilities had a median value of $5.2 million in 2019 and averaged $7.5 million.
  • Examining YoY changes over the last 5 years, Outlook Therapeutics' Preferred Stock Liabilities showed a top increase of 6840.6% in 2019 and a maximum decrease of 7245.56% in 2019.
  • Quarter analysis of 4 years shows Outlook Therapeutics' Preferred Stock Liabilities stood at $17.2 million in 2017, then crashed by 71.58% to $4.9 million in 2018, then surged by 68.41% to $8.2 million in 2019, then decreased by 21.38% to $6.5 million in 2020.
  • Its Preferred Stock Liabilities stands at $6.5 million for Q1 2020, versus $8.2 million for Q4 2019 and $5.4 million for Q3 2019.